Updated prognostic factors in localized NSCLC
Simple Summary In resected lung cancer, adjuvant and neoadjuvant chemotherapy
following surgery are currently mainly based on TNM classification. With the validation and …
following surgery are currently mainly based on TNM classification. With the validation and …
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
M Canale, K Andrikou, I Priano, P Cravero, L Pasini… - Cancers, 2022 - mdpi.com
Simple Summary Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …
The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Purpose: SMARCA4 mutations are among the most common recurrent alterations in non–
small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and …
small cell lung cancer (NSCLC), but the relationship to other genomic abnormalities and …
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC
J Yun, SH Lee, SY Kim, SY Jeong, JH Kim, KH Pyo… - Cancer Discovery, 2020 - AACR
EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer
(NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ …
(NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ …
[HTML][HTML] Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes
Introduction EGFR-mutant lung cancers are clinically and genomically heterogeneous with
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations …
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations …
Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience
Purpose: Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered
metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered …
metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered …
[HTML][HTML] Comprehensive analysis of TP53 and KEAP1 mutations and their impact on survival in localized-and advanced-stage NSCLC
MM Saleh, M Scheffler, S Merkelbach-Bruse… - Journal of Thoracic …, 2022 - Elsevier
Introduction TP53 and KEAP1 are frequently mutated in NSCLC, but their prognostic value is
ambiguous, particularly in localized stage tumors. Methods This retrospective cohort study …
ambiguous, particularly in localized stage tumors. Methods This retrospective cohort study …
[HTML][HTML] Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung …
D Planchard, PH Feng, N Karaseva, SW Kim, TM Kim… - ESMO open, 2021 - Elsevier
Background The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib …
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis …
L Zhang, L Wang, J Wang, J Chen, Z Meng, Z Liu… - Molecular Cancer, 2023 - Springer
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study …
[HTML][HTML] Osimertinib in NSCLC with atypical EGFR-activating mutations: a retrospective multicenter study
J Ji, JV Aredo, A Piper-Vallillo, L Huppert… - JTO clinical and …, 2023 - Elsevier
Introduction EGFR mutations drive a subset of NSCLC. Patients harboring the common
EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third …
EGFR mutations, deletion of exon 19 and L858R, respond well to osimertinib, a third …